Product Code: ETC13307239 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Cell Gene Therapy CDMO Market was valued at USD 4.8 Billion in 2024 and is expected to reach USD 13.4 Billion by 2031, growing at a compound annual growth rate of 6.90% during the forecast period (2025-2031).
The Global Cell Gene Therapy CDMO (Contract Development and Manufacturing Organization) Market is experiencing significant growth driven by the increasing demand for personalized medicine and advanced therapies. CDMOs in this market provide services such as process development, manufacturing, and regulatory support for cell and gene therapy products. Key factors contributing to market expansion include the rise in clinical trials for cell and gene therapies, advancements in biotechnology, and the need for specialized expertise and infrastructure. The market is characterized by collaborations between pharmaceutical companies and CDMOs to accelerate product development and commercialization. Geographically, North America and Europe are key regions for the Cell Gene Therapy CDMO market, but emerging markets in Asia-Pacific are also showing promising growth opportunities. Overall, the market is poised for continued expansion as the demand for innovative therapies continues to rise globally.
The Global Cell Gene Therapy CDMO market is experiencing significant growth driven by the increasing adoption of personalized medicine and advancements in biotechnology. Key trends include a rise in outsourcing of cell and gene therapy manufacturing to Contract Development and Manufacturing Organizations (CDMOs) due to complex manufacturing processes and the need for specialized expertise. Opportunities in the market lie in the development of innovative therapies for rare diseases, oncology, and autoimmune disorders, as well as the expansion of CDMOs` capabilities to meet the growing demand. Collaboration between biopharmaceutical companies and CDMOs, technological advancements, and favorable regulatory environments are also contributing to the market`s expansion. Overall, the Global Cell Gene Therapy CDMO market is poised for continued growth and evolution in the coming years.
The Global Cell Gene Therapy CDMO (Contract Development and Manufacturing Organization) Market faces several challenges, including regulatory complexities and stringent quality standards, high production costs due to the specialized nature of cell and gene therapy manufacturing processes, and limited manufacturing capacity and expertise within the industry. Additionally, there is a need for continued innovation and technological advancements to optimize manufacturing processes and improve scalability to meet the increasing demand for cell and gene therapy products. The market also faces challenges related to intellectual property rights, supply chain disruptions, and the need for skilled workforce and training programs to support the growth of the industry. Overcoming these challenges will be crucial for the continued expansion and success of the Global Cell Gene Therapy CDMO Market.
The Global Cell Gene Therapy CDMO (Contract Development and Manufacturing Organization) Market is being primarily driven by the increasing demand for personalized medicine, advancements in cell and gene therapy technologies, and the rising prevalence of chronic diseases such as cancer and genetic disorders. The outsourcing of manufacturing and development activities to CDMOs allows companies to leverage specialized expertise, reduce costs, and accelerate the commercialization of cell and gene therapy products. Additionally, the growing number of collaborations between pharmaceutical companies and CDMOs, along with favorable regulatory guidelines supporting the development of advanced therapies, are further propelling the market growth. Overall, the need for efficient and scalable manufacturing solutions to meet the increasing demand for cell and gene therapies is fueling the expansion of the Global Cell Gene Therapy CDMO Market.
Government policies related to the Global Cell Gene Therapy CDMO Market primarily focus on regulation, safety, and ethical considerations. Regulatory bodies such as the FDA in the United States and the EMA in Europe have established guidelines to ensure the quality, safety, and efficacy of cell and gene therapy products. These policies require CDMOs to adhere to strict manufacturing standards, conduct thorough testing, and comply with reporting requirements. Additionally, government funding and incentives are often provided to support research and development in this innovative field. Ethical considerations regarding patient consent, data privacy, and equitable access to therapies also play a significant role in shaping government policies related to the Global Cell Gene Therapy CDMO Market. Overall, these policies aim to promote innovation while safeguarding public health and ensuring ethical practices in the rapidly evolving field of cell and gene therapy.
The Global Cell Gene Therapy CDMO (Contract Development and Manufacturing Organization) Market is expected to witness substantial growth in the coming years as the demand for personalized medicine and advanced cell and gene therapies continues to rise. Factors driving this growth include increased investment in research and development, expanding collaborations between biopharmaceutical companies and CDMOs, and advancements in technology leading to more efficient manufacturing processes. Additionally, the growing pipeline of cell and gene therapy products in various stages of development is expected to create opportunities for CDMOs to offer their services. However, challenges such as regulatory complexities, high costs associated with manufacturing, and the need for specialized expertise may hinder the market growth to some extent. Overall, the Global Cell Gene Therapy CDMO Market is projected to experience significant expansion in the foreseeable future.
The Global Cell Gene Therapy CDMO market is poised for significant growth across all regions, with Asia showing the highest potential for expansion due to increasing investments in healthcare infrastructure and rising adoption of advanced therapies. North America is expected to maintain its dominance in the market, driven by a robust regulatory framework and strong R&D capabilities. In Europe, the market is witnessing steady growth supported by favorable government initiatives and a growing focus on personalized medicine. The Middle East and Africa region is gradually entering the cell gene therapy CDMO market, with improving healthcare systems and rising awareness about innovative treatment options. Latin America is also showing promise with a growing number of clinical trials and collaborations with global pharmaceutical companies, indicating a favorable market outlook in the region.
Global Cell Gene Therapy CDMO Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Cell Gene Therapy CDMO Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Cell Gene Therapy CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Global Cell Gene Therapy CDMO Market - Industry Life Cycle |
3.4 Global Cell Gene Therapy CDMO Market - Porter's Five Forces |
3.5 Global Cell Gene Therapy CDMO Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Cell Gene Therapy CDMO Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Global Cell Gene Therapy CDMO Market Revenues & Volume Share, By Technology Type, 2021 & 2031F |
3.8 Global Cell Gene Therapy CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Global Cell Gene Therapy CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Global Cell Gene Therapy CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Cell Gene Therapy CDMO Market Trends |
6 Global Cell Gene Therapy CDMO Market, 2021 - 2031 |
6.1 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Viral Vector Manufacturing, 2021 - 2031 |
6.1.3 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Plasmid DNA Manufacturing, 2021 - 2031 |
6.1.4 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Cell Therapy Manufacturing, 2021 - 2031 |
6.1.5 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Cryopreservation Services, 2021 - 2031 |
6.2 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Lentiviral Vector Technology, 2021 - 2031 |
6.2.3 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Plasmid-Based Gene Delivery, 2021 - 2031 |
6.2.4 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By CAR-T Cell Expansion Technology, 2021 - 2031 |
6.2.5 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Controlled-Rate Freezing, 2021 - 2031 |
6.3 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Biopharmaceutical Companies, 2021 - 2031 |
6.3.3 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Research Institutes, 2021 - 2031 |
6.3.4 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Hospitals and Clinics, 2021 - 2031 |
6.3.5 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Cell and Gene Therapy Developers, 2021 - 2031 |
6.4 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Gene Delivery for Cell Therapy, 2021 - 2031 |
6.4.3 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Preclinical and Clinical Studies, 2021 - 2031 |
6.4.4 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Oncology and Rare Diseases Treatment, 2021 - 2031 |
6.4.5 Global Cell Gene Therapy CDMO Market, Revenues & Volume, By Transport of Cell Therapies, 2021 - 2031 |
7 North America Cell Gene Therapy CDMO Market, Overview & Analysis |
7.1 North America Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
7.2 North America Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.4 North America Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
7.5 North America Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6 North America Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
8 Latin America (LATAM) Cell Gene Therapy CDMO Market, Overview & Analysis |
8.1 Latin America (LATAM) Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.4 Latin America (LATAM) Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
8.5 Latin America (LATAM) Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
8.6 Latin America (LATAM) Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
9 Asia Cell Gene Therapy CDMO Market, Overview & Analysis |
9.1 Asia Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.4 Asia Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
9.5 Asia Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
9.6 Asia Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
10 Africa Cell Gene Therapy CDMO Market, Overview & Analysis |
10.1 Africa Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.4 Africa Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
10.5 Africa Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
10.6 Africa Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
11 Europe Cell Gene Therapy CDMO Market, Overview & Analysis |
11.1 Europe Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.4 Europe Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
11.5 Europe Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
11.6 Europe Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
12 Middle East Cell Gene Therapy CDMO Market, Overview & Analysis |
12.1 Middle East Cell Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Cell Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Cell Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Cell Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.4 Middle East Cell Gene Therapy CDMO Market, Revenues & Volume, By Technology Type, 2021 - 2031 |
12.5 Middle East Cell Gene Therapy CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
12.6 Middle East Cell Gene Therapy CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
13 Global Cell Gene Therapy CDMO Market Key Performance Indicators |
14 Global Cell Gene Therapy CDMO Market - Export/Import By Countries Assessment |
15 Global Cell Gene Therapy CDMO Market - Opportunity Assessment |
15.1 Global Cell Gene Therapy CDMO Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Cell Gene Therapy CDMO Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.3 Global Cell Gene Therapy CDMO Market Opportunity Assessment, By Technology Type, 2021 & 2031F |
15.4 Global Cell Gene Therapy CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
15.5 Global Cell Gene Therapy CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
16 Global Cell Gene Therapy CDMO Market - Competitive Landscape |
16.1 Global Cell Gene Therapy CDMO Market Revenue Share, By Companies, 2024 |
16.2 Global Cell Gene Therapy CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |